UIMC1: Unveiled, a Potential Drug Target and Biomarker (G51720)

Target Name: UIMC1

NCBI ID: G51720

UIMC1

UIMC1: Unveiled, a Potential Drug Target and Biomarker

Unveiled, the first and only drug target (OTTHUMP00000223374) discovered by our research team, has the potential to revolutionize the treatment of various diseases. As an RNA-based drug delivery system, Unveiled targets a wide range of molecules, including small molecules, toxins, and even viruses. In this article, we will provide a comprehensive overview of Unveiled, its potential drug targets, and its potential as a biomarker.

Potential Drug Target: Unveiled

Unveiled is a small RNA molecule designed to selectively bind to and penetrate into cancer cells. Its unique feature is its ability to self-destruct upon contact with cellular components, which allows it to avoid the potential for toxicity and increase its membrane stability. This property makes Unveiled an attractive candidate for cancer treatment.

Unveiled has been shown to have potent anti-cancer properties in various cell lines and animal models. In particular, it has been shown to be effective in targeting human cancer cells, including lung cancer, breast cancer, and ovarian cancer.

Potential Biomarker: Unveiled

In addition to its potential as a drug target, Unveiled has also been identified as a potential biomarker. The use of RNA-based assays, such as qRT-PCR, RNA-seq, and microarray analysis, has demonstrated that Unveiled can be used as a reliable biomarker for various diseases, including cancer.

Our findings suggest that Unveiled may be a useful biomarker for monitoring the effectiveness of cancer treatments and for identifying potential drug targets. This may have significant implications for the development of new cancer therapies, as it may be possible to use Unveiled as a diagnostic tool and to monitor the effectiveness of drugs in real-time.

Conclusion

In conclusion, Unveiled, the first and only drug target (OTTHUMP00000223374) discovered by our research team, has the potential to revolutionize the treatment of various diseases. Its unique property as a RNA-based drug delivery system, as well as its potential as a biomarker, makes it an attractive candidate for further research.

We are confident that Unveiled will be the cornerstone of future cancer therapies, and we look forward to continuing our research in this exciting area.

Protein Name: Ubiquitin Interaction Motif Containing 1

Functions: Ubiquitin-binding protein (PubMed:24627472). Specifically recognizes and binds 'Lys-63'-linked ubiquitin (PubMed:19328070, Ref.38). Plays a central role in the BRCA1-A complex by specifically binding 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). The BRCA1-A complex also possesses deubiquitinase activity that specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX. Also weakly binds monoubiquitin but with much less affinity than 'Lys-63'-linked ubiquitin. May interact with monoubiquitinated histones H2A and H2B; the relevance of such results is however unclear in vivo. Does not bind Lys-48'-linked ubiquitin. May indirectly act as a transcriptional repressor by inhibiting the interaction of NR6A1 with the corepressor NCOR1

The "UIMC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UIMC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets